TY -的A2 Colosimo卡罗盟——Szasz Jozsef匈奴王盟,Jianu德拉戈铸塑酚醛塑料盟——一场,里面阿德里亚娜盟,江诗丹顿Viorelia Adelina AU - Dulamea,阿德里亚娜Octaviana盟——Onuk Koray盟——Popescu戴安娜AU -瓦西,Mihai-Titus盟——Popescu Bogdan Ovidiu AU -法,阿方索盟——Bajenaru Ovidiu Alexandru PY - 2021 DA - 2021/01/25 TI -描述高级帕金森病:罗马尼亚Subanalysis OBSERVE-PD研究SP - 6635618六世- 2021 AB - OBSERVE-PD横断面,多国,观察研究在128年进行的运动障碍中心(mdc)在18个国家。总的来说,这项研究招收了2615名病人。目的是确定晚期帕金森症患者的比例(adp)与non-APD MDCs和发现临床adp的负担,以及联系美国adp和几个指标的总体评估。疾病的晚期和严重程度进行了评估,调查人员使用他们的临床判断。数据被收集在一个单一的访问在2015年2月和2016年1月之间。美国医生判断协议的诊断和满足美国至少有一个先前建立的指标计算。电动机和nonmotor症状(nms),日常生活的活动,处理并发症,生活质量(QoL),常规治疗,device-aided疗法(DAT)资格评估。这里,国家161罗马尼亚PD患者的结果。总的来说,59.0%的患者被诊断为美国adp和78.8%遇到至少一个指示器。只有温和的协议之间的临床判断美国adp和整体实现的指标。 All scores related to motor symptoms, NMSs, and treatment complications, as well as to QoL, showed a higher disease burden for patients with APD versus non-APD. Physicians considered 73.7% of patients with APD eligible for DAT. The majority of patients eligible for DAT (54.3%) did not receive such treatment. Our results highlight the importance of earlier recognition of APD, by combining clinical judgement with more standardized clinical tools, such as generally recognized APD criteria. However, timely diagnosis of APD alone is not enough to improve patient outcomes. Other critical factors include patient acceptance and access to appropriate treatment. SN - 2090-8083 UR - https://doi.org/10.1155/2021/6635618 DO - 10.1155/2021/6635618 JF - Parkinson’s Disease PB - Hindawi KW - ER -